OncoMatch

OncoMatch/Clinical Trials/NCT06884618

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

Is NCT06884618 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies RO7673396 for neoplasms.

Phase 1RecruitingHoffmann-La RocheNCT06884618Data as of Sep 2026Location: International · 10 countries

Treatment: RO7673396 — This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

RO7673396

Cancer type

Tumor Agnostic

Biomarker criteria

Required: HRAS mutation

Required: KRAS mutation

Required: NRAS mutation

Performance status

ECOG 0–1(Restricted strenuous activity)

Lab requirements

Blood counts

Adequate hematologic function

Kidney function

Adequate end-organ function

Liver function

Adequate end-organ function

Adequate hematologic and end-organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope Comprehensive Cancer Center · Duarte, California
  • University of Colorado - Anschutz Medical Campus - PPDS · Aurora, Colorado
  • Smilow Cancer Hospital at Yale New Haven · New Haven, Connecticut
  • Florida Cancer Specialists - Sarasota (North Catttlemen Rd) · Sarasota, Florida
  • MD Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06884618 currently recruiting?

Yes, this trial is currently recruiting patients.

Does this trial require HRAS?

Yes, HRAS mutation is a required biomarker for enrollment.

Does this trial require KRAS?

Yes, KRAS mutation is a required biomarker for enrollment.

Does this trial require NRAS?

Yes, NRAS mutation is a required biomarker for enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify